-
Red Light, Green Light: How Huntingtonās Disease Influences Genetic Traffic Lights
Latest News
-
Revisiting vitamin therapy for HD
A small clinical trial of high-dose biotin and thiamine for treating HD is being planned in Spain. This trial is based on research that links HD to another neurodegenerative disease called biotin-thiamine responsive basal ganglia disease (BTBGD).
-
A spoonful of branaplam helps the huntingtin go down
Branaplam was originally designed to treat spinal muscular atrophy, but a new paper outlines how it could hold promise for treating Huntingtonās. This oral drug lowers huntingtin protein and will now be tested in a study called VIBRANT-HD.
-
Huntingtonās disease therapeutics conference 2022 – Day 3
Check out research updates from Day 3 of the 2022 HD Therapeutics Conference #HDTC2022
-
Huntingtonās disease therapeutics conference 2022 – Day 1
Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2022
-
Huntingtonās disease therapeutics conference 2022 – Day 2
Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2022
-
Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
A new imaging tool means that scientists can now directly measure the levels of the toxic huntingtin protein in animal models of Huntingtonās disease, letting us see how well huntingtin lowering therapies are working in their brains
-
BAC to basics: a more accurate mouse model for Huntington's disease
A genetically-tweaked Huntington's disease mouse model shows a tendency for the CAG repeat to grow, just like we see in humans with the mutation.
-
Oral drug may change the story for huntingtin lowering
Researchers with PTC Therapeutics recently published exciting new findings – a promising new huntingtin lowering drug that can be taken as a pill. Will this change how we move forward with huntingtin lowering?
-
Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
The first round of findings from the halted tominersen huntingtin lowering trial, GENERATION-HD1, run by Roche were shared this week with the HD community. HDBuzz explains what they found and whatās next.
-
KINECT-HD trial shows valbenazine improves involuntary movements in Huntington's disease
In a much-needed bit of good news for the Huntington's disease community, Neurocrine Bioscience's KINECT-HD trial showed that treatment with valbenazine significantly reduced the involuntary movements called chorea